The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya.
- Resource Type
- Academic Journal
- Authors
- Ochola-Oyier LI; Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya liochola@kemri-wellcome.org.; Okombo J; Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.; Mwai L; Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.; Kiara SM; Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.; Pole L; Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.; Tetteh KK; Department of Immunology & Infection, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.; Nzila A; King Fahd University of Petroleum and Minerals, Department of Biology, Dhahran, Saudi Arabia.; Marsh K; Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.
- Source
- Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE
- Subject
- Language
- English
The mechanisms of drug resistance development in the Plasmodium falciparum parasite to lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We assessed the polymorphisms of Pfmspdbl2 for associations with LUM activity in a Kenyan population. MSPDBL2 codon 591S was associated with reduced susceptibility to LUM (P = 0.04). The high frequency of Pfmspdbl2 codon 591S in Kenya may be driven by the widespread use of lumefantrine in artemisinin combination therapy (Coartem).
(Copyright © 2015, Ochola-Oyier et al.)